Updated: July 5, 2024     Source: suse.edu.cn

On the afternoon of July 2, Dr. Deng Xuewen, deputy director of the Japanese Institute of Biotherapy, visited the Libaihe Campus of SUSE and brought an excellent academic report titled “The Current Situation and Prospects of Biologic Immunotherapy at Home and Abroad” for teachers and students. Zhang Li, secretary of the Party Committee of SUSE, Tuo Xianguo, deputy secretary of the Party Committee and president of SUSE, Li Chengjun, former secretary of the Party Committee of North Sichuan Medical College, Zhang Cheng, secretary of the Party Committee of the Fourth People's Hospital of Zigong City, the heads of various departments of the Fourth People's Hospital of Zigong City, the heads of the Science and Technology Department and relevant schools of SUSE, academic backbones, and representatives of postgraduate students participated. The report meeting was chaired by Gao Xiaolin, member of the Standing Committee of the Party Committee and Vice President of the SUSE.

Being rich in content, Dr. Deng Xuewen's report explained the latest progress and future trends of biologic immunotherapy technology in a simple and easy-to-understand manner. He pointed out that cellular biologic immunotherapy, as the fourth major tumor treatment technology after surgery, radiotherapy, and chemotherapy, is gradually becoming an important force in the field of tumor treatment. This technology stimulates and enhances the body's own immune function by culturing and expanding the patient's own immune cells in vitro and then transfusing them back into the body, so as to achieve the purpose of treating tumors. It has remarkable curative effects and broad application prospects. Meanwhile, Dr. Deng also introduced the innovative achievements of his team in the technology of large-scale expansion and culture of NK cells, shared in-depth research and clinical application experiences in the field of immune cells, and demonstrated the broad application prospects of biologic immunotherapy in tumor treatment.

The atmosphere at the report meeting was lively. The participating teachers, students, and guests raised questions one after another regarding the technical details, clinical applications, and policy impacts of biologic immunotherapy. Dr. Deng Xuewen patiently answered them one by one. Lastly, he encouraged everyone to maintain enthusiasm and curiosity for scientific research and jointly promote the progress and development of biologic immunotherapy technology.

In his summary, Gao Xiaolin said that Dr. Deng Xuewen's outstanding achievements in the field of tumor immunotherapy, especially the world-leading breakthrough in NK cell culture technology, have not only brought substantial treatment benefits to patients but also set an example of scientific research innovation for the global medical community. He hoped that all teachers and students of SUSE would cherish this rare learning opportunity, deeply understand the scientific research wisdom and innovation spirit contained in Dr. Deng Xuewen's report, and promote the continuous improvement of the scientific research in the medical field of SUSE.